In clinical trials of givinostat as a [[salvage therapy]] for advanced [[Hodgkin's lymphoma]], the most common [[adverse drug reaction|adverse reactions]] were [[fatigue (medical)|fatigue]] (seen in 50% of participants), mild diarrhea or abdominal pain (40% of participants), moderate [[thrombocytopenia]] (decreased [[platelet]] counts, seen in one third of patients), and mild [[leukopenia]] (a decrease in [[white blood cell]] levels, seen in 30% of patients). One-fifth of patients experienced [[QT interval#Due to adverse drug reactions|prolongation]] of the [[QT interval]], a measure of electrical conduction in the heart, severe enough to warrant temporary suspension of treatment.<ref name=Tan>Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2827364 "Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents".] ''Journal of Hematology & Oncology'' '''3''': 5. {{doi|10.1186/1756-8722-3-5}}. {{PMID|20132536}}. Review.</ref>

 

